CClinicalTrials.gg
Sign In
CompletedNCT07825636Updated Sep 17, 2026

Sensorimotor Function in COPD

An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Alanya Alaaddin Keykubat University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Alanya Alaaddin Keykubat University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
95
Ages
40 Years to 65 Years
Sex
All
01

Study summary

The aim of this study was to investigate the level of sensorimotor function impairment according to disease stage in individuals with Chronic Obstructive Pulmonary Disease (COPD) and to determine whether functional differences exist between individuals with COPD and healthy controls.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Muscle dysfunction
  • Proprioception
  • Pain
  • Cognitive impairment
03

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals diagnosed with COPD or healthy controls between the age of 40-65 years.

Eligibility criteria

Inclusion Criteria:

Individuals diagnosed with COPD,

  • Aged 40-65 years, who volunteer to participate in the study,
  • Who do not have additional musculoskeletal disorders, neurological or cardiorespiratory problems, or respiratory failure (not using long-term home oxygen therapy or non-invasive mechanical ventilation) will be included.

Inclusion Criteria for Healthy Individuals:

  • Individuals aged 40-65 years who volunteer to participate in the study,
  • Who do not have additional musculoskeletal disorders, neurological or cardiorespiratory problems,
  • Who do not have communication problems will be included.

Exclusion Criteria:

Exclusion Criteria for Individuals with COPD

  • Individuals with uncorrected visual and hearing impairment,
  • Individuals with a diagnosed serious chronic disease (neurological disease, cancer, chronic heart failure, etc.).

Exclusion Criteria for Healthy Individuals

  • Individuals with uncorrected visual and hearing impairment,
  • A diagnosed serious chronic disease (neurological disease, cancer, chronic heart failure, etc.) will be excluded from the study.
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
95 participants (actual)
Patient registry
No

Groups and cohorts

  • COPD Group
  • Healthy Control
05

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment

    Cognitive function was assessed using the Montreal Cognitive Assessment. The scale evaluates various cognitive domains, such as executive functions, visuospatial skills, attention, memory, language, abstraction, and orientation. The total score was calculated out of 30 points.

    Time frame: Enrollment

  2. Pain Pressure Threshold and Tolerance

    Pain threshold and pain tolerance were assessed using a digital pressure algometer (J-Tech Commander algometer, Preston Co., USA). Two measurements were taken from each site, and the mean value was used in the analysis.

    Time frame: Enrollment

  3. Muscle Quality Index

    Muscle quality was assessed using the Muscle Quality Index, calculated based on the duration of the 5-repetition sit-to-stand test, body weight, and leg length.

    Time frame: Enrollment

Secondary outcomes

  1. Lower Extremity Coordination Test

    Lower extremity coordination was assessed using the Lower Extremity Coordination Test, performed as a heel-to-toe tapping task. The test is repeated three times over a 20-second period, and the best result is used in the analysis.

    Time frame: Enrollment

06

Study locations

1 site
  • Alanya Alaaddin Keykubet University
    Antalya, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07825636
Lead sponsor
Alanya Alaaddin Keykubat University
Responsible party
Ayse Unal (Assoc. Prof, PT.PhD., Alanya Alaaddin Keykubat University) — Principal investigator
First posted
Sep 17, 2026
Start date
Oct 1, 2024
Primary completion
May 1, 2026
Completion
Jul 1, 2026
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary Disease, Chronic Obstructive→

Other studies from this sponsor

Alanya Alaaddin Keykubat University

Start the discussion